Genix Pharmaceuticals Corporation
GENX.V
TSX
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -65.00% | -65.00% | -91.67% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -65.00% | -65.00% | -91.67% |
| Cost of Revenue | -- | -- | 0.00% | -82.76% | -100.00% |
| Gross Profit | -- | -- | -70.59% | 1,100.00% | -100.00% |
| SG&A Expenses | -28.28% | -43.36% | 63.04% | -45.03% | -52.10% |
| Depreciation & Amortization | 0.00% | -99.80% | -99.80% | -99.80% | -99.80% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.33% | -0.06% | -74.71% | -81.01% | -81.83% |
| Operating Income | 28.09% | 0.11% | 74.87% | 81.69% | 81.76% |
| Income Before Tax | -72.77% | 104.06% | 51.22% | 63.37% | 74.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -72.77% | 104.06% | 51.22% | 63.37% | 74.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -72.77% | 104.06% | 51.22% | 63.37% | 74.05% |
| EBIT | 28.09% | 0.11% | 74.87% | 81.69% | 81.76% |
| EBITDA | 28.28% | 1.13% | 514.97% | 234.59% | 51.63% |
| EPS Basic | -85.71% | 104.05% | 52.38% | 62.07% | 75.00% |
| Normalized Basic EPS | -60.00% | -4.17% | 53.85% | 61.11% | 72.22% |
| EPS Diluted | -85.71% | 104.05% | 52.38% | 62.07% | 75.00% |
| Normalized Diluted EPS | -60.00% | -4.17% | 53.85% | 61.11% | 72.22% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |